Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.
D001932:Brain Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000134:cerebrospinal fluid / Q000627:therapeutic use / Q000652:urine; D005069:Evaluation Studies as Topic; D006207:Half-Life; D006413:Hematopoietic System / Q000187:drug effects; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008107:Liver Diseases / Q000150:complications; D008223:Lymphoma / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D012075:Remission, Spontaneous; D012509:Sarcoma / Q000188:drug therapy
D004317:Doxorubicin